image

Hormone Replacement Therapy Market Report Scope & Overview:

Hormone Replacement Therapy Market,Revenue Analysis

Get More Information on Hormone Replacement Therapy Market - Request Sample Report

The Hormone Replacement Therapy Market Size was valued at USD 18.36 billion in 2023 and is expected to reach USD 29.02 billion by 2032 and grow at a CAGR of 5.31% over the forecast period 2024-2032. 

The hormone replacement therapy (HRT) market is expected to increase due to the rising prevalence of post-menopausal Problems, and hormonal imbalance cases along with geriatric population. World Population Prospects 2022 reported that the latest estimates of global population UN projections suggest that there will be nearly 8.5 billion people alive in the year 2021, with the last projection for their number to rise to 9.7 billion by 2050 and then further increase by billion.  Most Importantly, characteristics of aging are the natural process that occurs after a certain age in every female with different hormonal changes, and hence disorders start to appear. Many of those issues are weight gain, memory loss, fatigue, and low libido which almost everyone suffers from in that situation as well. Others may develop an aging appearance or even experience slight muscle wasting.

The most commonly experienced effect of age-related hormonal shifts is seen with menopausal cases. The typical age range for the onset of menopause in women is around 50 years globally. Women's estrogen and progesterone production falls significantly with age from around 50 years. According to the North American Menopause Society (NAMS), more than 1.3 million women transition through menopause per year.  About nine in every ten postmenopausal women will have experienced at least one symptom of menopause with the most common being hot flushes and night sweats. These hormonal changes are natural with aging and do not represent a disease. Such factors skyrocket the market for hormonal replacement therapy which leads to increasing need and in turn supports the demand for hormone replacement therapy..

KEY DRIVERS:

  • Raising Awareness of Post-Menopausal Complications Amongst Women is Fuelling the Demand for Hormone Replacement Therapy Market.
  • The Rising Geriatric Population Led to Hormonal Imbalance Disorders Raising the Demand for Hormone Replacement Therapy Which is Boosting Market Growth.

RESTRAINTS:

  • Substantial Risk of Cancer Regarding Hormone Replacement Therapy are Hindering Hormone Replacement Therapy Market Growth.
  • The Higher Costs of Hormone Replacement Therapy Limit the Adoption of Hormone Replacement Therapy.

OPPORTUNITY:

  • Technological Advancements are Offering a Lucrative Growth Opportunity for Hormone Replacement Therapy Systems.
  • Investment in R&D is Responsible for the Hormone Replacement Therapy System Market Growth During Upcoming Years.

KEY MARKET SEGMENTATION:

By Route of Administration

  • Oral
  • Parenteral
  • Transdermal
  • Others

Based on route of administration, High prescription rate and ease of administration led the oral segment to hold a major market share accounting for 43.06% in 2023. It is most commonly given in the form of hormonal replacement therapy pills & tablets itself. Additionally, the introduction of a new long-acting growth hormone injection is expected to further parenteral segment expansion. Now, a couple of examples in our industry are Pfizer Inc. and OPKO Health Inc., which in January 2022 gained approval from the MHLW for NGENLA to treat growth hormone disorder on its way toward commercialization. This product is a weekly injectable long-acting growth hormone. Thus, the aforementioned factors are bolstering the hormone replacement therapy market growth.

By Disease Type

  • Menopause
  • Hypothyroidism
  • Male hypogonadism
  • Growth hormone deficiency
  • Hypoparathyroidism

Menopause application held the largest market share of 45.03% in 2023 owing to rising geriatric population across the globe. The Women face mood swings, depression, and anxiety brought on by hormonal transition at the end of the reproductive stage; estrogen levels go down. Estrogen hormone replacement therapy is vital to minimize the complications of aging women-related menopause.

As per the research article -Prevalence and risk factors for menopausal symptoms in middle-aged Chinese women: a community-based cross-sectional study, which was published in November 2021; the prevalence of Menopausal Symptoms was found to be (303/3256=9.3%) (293/1227=23.9%), and (405/1881) =21.5%, while in reproductive stage, Menopause transition & postmenopausal stage respectively. An approach also has previously highlighted these trends in an entitled, and February 2021-published article Korea-style Menopausal Women estimated to have a quarter of active post-menopause vision in elderly women today will be nearly half. Postmenopausal women will comprise 59.8% of the female population expanded by age to year 2060. Therefore, menopause during the transition of life requires therapy for symptoms as would a combination treatment with levonorgestrel releasing-intrauterine system oral or percutaneous route, low-dose hormonal contraceptives, along with estrogen-progestogen therapy. Thus, the menopause indication segment is witnessed to achieve significant growth over the forecast period.

By Product

  • Estrogen & Progesterone Replacement Therapy
  • HGH replacement therapy
  • Thyroid hormone replacement therapy
  • Testosterone Replacement Therapy
  • Parathyroid Hormone Replacement

Regional Analysis :

In 2023, North America dominated the market with a market share of 40%. The rise in the geriatric population is one of the major drivers for hormonal replacement therapy market induction particularly across North America including the U.S. and Canada. Nearly half of post-menopausal women in the United States have used some form of HRT according to the National Institutes of Health. Also, as per the Statpearls 2021 research article, nearly a million US women experience menopause every year. No such "other candidates" emerged to replace conjugated equine estrogens (CEE)/bazedoxifene tablet, the estrogen and selective estrogen receptor modulator combination approved in the U.S. for the treatment of Vasomotor Symptoms (VMS) associated with menopause along with osteoporosis prevention.

According to the American Thyroid Association (ATA), of 2022, over 12% are apt to develop a thyroid disorder in their lifetime, and nearly 20 million Americans have some form of thyroid disease each year. Consequently, the high prevalence of thyroid hormone imbalances in the population across the United States is anticipated to drive the growth of the human replacement therapy market under study.

In June 2022, Astellas Pharma Inc. submitted an NDA for fezolinetant to the USFDA So, an increasing trend in product approvals is also anticipated to propel the hormone replacement therapy market studied in the region. In the end, North America holds a high growth in the market for hormone replacement therapy throughout the forecast period. The high incidence rate of osteoporosis and increased patient awareness levels are expected to be driving factors for the hormone replacement therapy market.

Hormone-Replacement-Therapy-Market-Regional-Analysis-2023

Get Customized Report as per Your Business Requirement - Request For Customized Report

REGIONAL COVERAGE:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Eastern Europe
      • Poland
      • Romania
      • Hungary
      • Turkey
      • Rest of Eastern Europe
    • Western Europe
      • Germany
      • France
      • UK
      • Italy
      • Spain
      • Netherlands
      • Switzerland
      • Austria
      • Rest of Western Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Vietnam
    • Singapore
    • Australia
    • Rest of Asia Pacific
  • Middle East & Africa
    • Middle East
      • UAE
      • Egypt
      • Saudi Arabia
      • Qatar
      • Rest of Middle East
    • Africa
      • Nigeria
      • South Africa
      • Rest of Africa
  • Latin America
    • Brazil
    • Argentina
    • Colombia
    • Rest of Latin America  

Key Players

The key market players include ASCEND Therapeutics US, LLC, Eli Lilly and Company, Viatris, Inc., Pfizer Inc., Bayer AG, Novo Nordisk A/S, Merck & Co., Inc., F. Hoffmann-La Roche Ltd., AbbVie, Inc. & other players. The market is not consolidated and it is a strong innovation-driven industry, there are big players on the global front. Moreover, the leading players are concentrating on expanding their global product portfolio through acquisitions and partnerships with aligned companies. For example, the US FDA in December 2020 approved VistaPharm's Thyquidity (levothyroxine) oral solution for use as replacement therapy for primary (thyroidal), secondary (pituitary), and tertiary hypothyroidism and approval to be used as adjunctive therapy to surgery and radioiodine management in managing thyrotropin-dependent well-differentiated thyroid cancer.

RECENT DEVELOPMENTS

  • In April 2023, Novo Nordisk got approval from the FDA for the new indication for Sogroya. These indications apply to children greater than or equal to 2.5 years old with growth failure due to inadequate endogenous GH secretion.
  • In June 2022, Halozyme Therapeutics, Inc., announced the launch of TLANDO (testosterone undecanoate) oral capsules by experienced testosterone replacement for treating adult men with conditions associated with a deficiency or absence of endogenous testosterone.

Hormone Replacement Therapy Market Report Scope:

Report Attributes Details
Market Size in 2023 US$ 18.36 Billion
Market Size by 2032 US$ 29.02 Billion
CAGR CAGR of 5.31% From 2024 to 2032
Base Year 2023
Forecast Period 2024-2032
Historical Data 2020-2022
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments •By Product (Estrogen & Progesterone Replacement Therapy, HGH replacement therapy, Thyroid hormone replacement therapy, Testosterone Replacement Therapy, Parathyroid Hormone Replacement)
•By Route of Administration (Oral, Parenteral, Transdermal, Others)
•By Disease Type (Menopause, Hypothyroidism, Male hypogonadism, Growth hormone deficiency, Hypoparathyroidism)
Regional Analysis/Coverage North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America)
Company Profiles ASCEND Therapeutics US, LLC, Eli Lilly and Company, Viatris, Inc., Pfizer Inc., Bayer AG, Novo Nordisk A/S, Merck & Co., Inc., F. Hoffmann-La Roche Ltd., AbbVie, Inc. among others
Key Drivers •Raising Awareness of Post-Menopausal Complications Amongst Women is Fuelling the Demand for Hormone Replacement Therapy Market.
•The Rising Geriatric Population Led to Hormonal Imbalance Disorders Raising the Demand for Hormone Replacement Therapy Which is Boosting Market Growth.
RESTRAINTS •Substantial Risk of Cancer Regarding Hormone Replacement Therapy are Hindering Hormone Replacement Therapy Market Growth.
•The Higher Costs of Hormone Replacement Therapy Limit the Adoption of Hormone Replacement Therapy.

 

Frequently Asked Questions

Ans: The rise in the awareness of the HRT.

Ans: The Hormone Replacement Therapy Market is growing at a CAGR of 6.97% From 2024-2032.

Ans: The market is divided into three segments Product, Route of Administration, and by Disease Type.

Ans: The North American market saw the greatest increase in terms of revenue in 2023. On the other hand, the Asia-Pacific market is anticipated to experience the largest CAGR in terms of revenue throughout the forecast period.

Ans : HRT carries certain health risks, and the equilibrium between benefits and risks should be carefully assessed for each individual

TABLE OF CONTENTS

1. Introduction

1.1 Market Definition

1.2 Scope

1.3 Research Assumptions

2. Industry Flowchart

3. Research Methodology

4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

5. Porter’s 5 Forces Model

6. Pest Analysis

7. Hormone Replacement Therapy Market Segmentation, By Product

7.1 Introduction

7.2 Estrogen & Progesterone Replacement Therapy

7.3 HGH replacement therapy

7.4 Thyroid hormone replacement therapy

7.5 Testosterone Replacement Therapy

7.6 Parathyroid Hormone Replacement

8. Hormone Replacement Therapy Market Segmentation, By Route of Administration

8.1 Introduction

8.2 Oral

8.3 Parenteral

8.4 Transdermal

8.5 Others

9. Hormone Replacement Therapy Market Segmentation, By Disease Type

9.1 Introduction

9.2 Menopause

9.3 Hypothyroidism

9.4 Male hypogonadism

9.5 Growth hormone deficiency

9.6 Hypoparathyroidism

10. Regional Analysis

10.1 Introduction

10.2 North America

10.2.1 Trend Analysis

10.2.2 North America Hormone Replacement Therapy Market by Country

10.2.3 North America Hormone Replacement Therapy Market By Product

10.2.4 North America Hormone Replacement Therapy Market By Route of Administration

10.2.5 North America Hormone Replacement Therapy Market By Disease Type

10.2.6 USA

10.2.6.1 USA Hormone Replacement Therapy Market By Product

10.2.6.2 USA Hormone Replacement Therapy Market By Route of Administration

10.2.6.3 USA Hormone Replacement Therapy Market By Disease Type

10.2.7 Canada

10.2.7.1 Canada Hormone Replacement Therapy Market By Product

10.2.7.2 Canada Hormone Replacement Therapy Market By Route of Administration

10.2.7.3 Canada Hormone Replacement Therapy Market By Disease Type

10.2.8 Mexico

10.2.8.1 Mexico Hormone Replacement Therapy Market By Product

10.2.8.2 Mexico Hormone Replacement Therapy Market By Route of Administration

10.2.8.3 Mexico Hormone Replacement Therapy Market By Disease Type

10.3 Europe

10.3.1 Trend Analysis

10.3.2 Eastern Europe

10.3.2.1 Eastern Europe Hormone Replacement Therapy Market by Country

10.3.2.2 Eastern Europe Hormone Replacement Therapy Market By Product

10.3.2.3 Eastern Europe Hormone Replacement Therapy Market By Route of Administration

10.3.2.4 Eastern Europe Hormone Replacement Therapy Market By Disease Type

10.3.2.5 Poland

10.3.2.5.1 Poland Hormone Replacement Therapy Market By Product

10.3.2.5.2 Poland Hormone Replacement Therapy Market By Route of Administration

10.3.2.5.3 Poland Hormone Replacement Therapy Market By Disease Type

10.3.2.6 Romania

10.3.2.6.1 Romania Hormone Replacement Therapy Market By Product

10.3.2.6.2 Romania Hormone Replacement Therapy Market By Route of Administration

10.3.2.6.4 Romania Hormone Replacement Therapy Market By Disease Type

10.3.2.7 Hungary

10.3.2.7.1 Hungary Hormone Replacement Therapy Market By Product

10.3.2.7.2 Hungary Hormone Replacement Therapy Market By Route of Administration

10.3.2.7.3 Hungary Hormone Replacement Therapy Market By Disease Type

10.3.2.8 Turkey

10.3.2.8.1 Turkey Hormone Replacement Therapy Market By Product

10.3.2.8.2 Turkey Hormone Replacement Therapy Market By Route of Administration

10.3.2.8.3 Turkey Hormone Replacement Therapy Market By Disease Type

10.3.2.9 Rest of Eastern Europe

10.3.2.9.1 Rest of Eastern Europe Hormone Replacement Therapy Market By Product

10.3.2.9.2 Rest of Eastern Europe Hormone Replacement Therapy Market By Route of Administration

10.3.2.9.3 Rest of Eastern Europe Hormone Replacement Therapy Market By Disease Type

10.3.3 Western Europe

10.3.3.1 Western Europe Hormone Replacement Therapy Market by Country

10.3.3.2 Western Europe Hormone Replacement Therapy Market By Product

10.3.3.3 Western Europe Hormone Replacement Therapy Market By Route of Administration

10.3.3.4 Western Europe Hormone Replacement Therapy Market By Disease Type

10.3.3.5 Germany

10.3.3.5.1 Germany Hormone Replacement Therapy Market By Product

10.3.3.5.2 Germany Hormone Replacement Therapy Market By Route of Administration

10.3.3.5.3 Germany Hormone Replacement Therapy Market By Disease Type

10.3.3.6 France

10.3.3.6.1 France Hormone Replacement Therapy Market By Product

10.3.3.6.2 France Hormone Replacement Therapy Market By Route of Administration

10.3.3.6.3 France Hormone Replacement Therapy Market By Disease Type

10.3.3.7 UK

10.3.3.7.1 UK Hormone Replacement Therapy Market By Product

10.3.3.7.2 UK Hormone Replacement Therapy Market By Route of Administration

10.3.3.7.3 UK Hormone Replacement Therapy Market By Disease Type

10.3.3.8 Italy

10.3.3.8.1 Italy Hormone Replacement Therapy Market By Product

10.3.3.8.2 Italy Hormone Replacement Therapy Market By Route of Administration

10.3.3.8.3 Italy Hormone Replacement Therapy Market By Disease Type

10.3.3.9 Spain

10.3.3.9.1 Spain Hormone Replacement Therapy Market By Product

10.3.3.9.2 Spain Hormone Replacement Therapy Market By Route of Administration

10.3.3.9.3 Spain Hormone Replacement Therapy Market By Disease Type

10.3.3.10 Netherlands

10.3.3.10.1 Netherlands Hormone Replacement Therapy Market By Product

10.3.3.10.2 Netherlands Hormone Replacement Therapy Market By Route of Administration

10.3.3.10.3 Netherlands Hormone Replacement Therapy Market By Disease Type

10.3.3.11 Switzerland

10.3.3.11.1 Switzerland Hormone Replacement Therapy Market By Product

10.3.3.11.2 Switzerland Hormone Replacement Therapy Market By Route of Administration

10.3.3.11.3 Switzerland Hormone Replacement Therapy Market By Disease Type

10.3.3.12 Austria

10.3.3.12.1 Austria Hormone Replacement Therapy Market By Product

10.3.3.12.2 Austria Hormone Replacement Therapy Market By Route of Administration

10.3.3.12.3 Austria Hormone Replacement Therapy Market By Disease Type

10.3.3.13 Rest of Western Europe

10.3.3.13.1 Rest of Western Europe Hormone Replacement Therapy Market By Product

10.3.3.13.2 Rest of Western Europe Hormone Replacement Therapy Market By Route of Administration

10.3.3.13.3 Rest of Western Europe Hormone Replacement Therapy Market By Disease Type

10.4 Asia-Pacific

10.4.1 Trend Analysis

10.4.2 Asia-Pacific Hormone Replacement Therapy Market by Country

10.4.3 Asia-Pacific Hormone Replacement Therapy Market By Product

10.4.4 Asia-Pacific Hormone Replacement Therapy Market By Route of Administration

10.4.5 Asia-Pacific Hormone Replacement Therapy Market By Disease Type

10.4.6 China

10.4.6.1 China Hormone Replacement Therapy Market By Product

10.4.6.2 China Hormone Replacement Therapy Market By Route of Administration

10.4.6.3 China Hormone Replacement Therapy Market By Disease Type

10.4.7 India

10.4.7.1 India Hormone Replacement Therapy Market By Product

10.4.7.2 India Hormone Replacement Therapy Market By Route of Administration

10.4.7.3 India Hormone Replacement Therapy Market By Disease Type

10.4.8 Japan

10.4.8.1 Japan Hormone Replacement Therapy Market By Product

10.4.8.2 Japan Hormone Replacement Therapy Market By Route of Administration

10.4.8.3 Japan Hormone Replacement Therapy Market By Disease Type

10.4.9 South Korea

10.4.9.1 South Korea Hormone Replacement Therapy Market By Product

10.4.9.2 South Korea Hormone Replacement Therapy Market By Route of Administration

10.4.9.3 South Korea Hormone Replacement Therapy Market By Disease Type

10.4.10 Vietnam

10.4.10.1 Vietnam Hormone Replacement Therapy Market By Product

10.4.10.2 Vietnam Hormone Replacement Therapy Market By Route of Administration

10.4.10.3 Vietnam Hormone Replacement Therapy Market By Disease Type

10.4.11 Singapore

10.4.11.1 Singapore Hormone Replacement Therapy Market By Product

10.4.11.2 Singapore Hormone Replacement Therapy Market By Route of Administration

10.4.11.3 Singapore Hormone Replacement Therapy Market By Disease Type

10.4.12 Australia

10.4.12.1 Australia Hormone Replacement Therapy Market By Product

10.4.12.2 Australia Hormone Replacement Therapy Market By Route of Administration

10.4.12.3 Australia Hormone Replacement Therapy Market By Disease Type

10.4.13 Rest of Asia-Pacific

10.4.13.1 Rest of Asia-Pacific Hormone Replacement Therapy Market By Product

10.4.13.2 Rest of Asia-Pacific Hormone Replacement Therapy Market By Route of Administration

10.4.13.3 Rest of Asia-Pacific Hormone Replacement Therapy Market By Disease Type

10.5 Middle East & Africa

10.5.1 Trend Analysis

10.5.2 Middle East

10.5.2.1 Middle East Hormone Replacement Therapy Market by Country

10.5.2.2 Middle East Hormone Replacement Therapy Market By Product

10.5.2.3 Middle East Hormone Replacement Therapy Market By Route of Administration

10.5.2.4 Middle East Hormone Replacement Therapy Market By Disease Type

10.5.2.5 UAE

10.5.2.5.1 UAE Hormone Replacement Therapy Market By Product

10.5.2.5.2 UAE Hormone Replacement Therapy Market By Route of Administration

10.5.2.5.3 UAE Hormone Replacement Therapy Market By Disease Type

10.5.2.6 Egypt

10.5.2.6.1 Egypt Hormone Replacement Therapy Market By Product

10.5.2.6.2 Egypt Hormone Replacement Therapy Market By Route of Administration

10.5.2.6.3 Egypt Hormone Replacement Therapy Market By Disease Type

10.5.2.7 Saudi Arabia

10.5.2.7.1 Saudi Arabia Hormone Replacement Therapy Market By Product

10.5.2.7.2 Saudi Arabia Hormone Replacement Therapy Market By Route of Administration

10.5.2.7.3 Saudi Arabia Hormone Replacement Therapy Market By Disease Type

10.5.2.8 Qatar

10.5.2.8.1 Qatar Hormone Replacement Therapy Market By Product

10.5.2.8.2 Qatar Hormone Replacement Therapy Market By Route of Administration

10.5.2.8.3 Qatar Hormone Replacement Therapy Market By Disease Type

10.5.2.9 Rest of Middle East

10.5.2.9.1 Rest of Middle East Hormone Replacement Therapy Market By Product

10.5.2.9.2 Rest of Middle East Hormone Replacement Therapy Market By Route of Administration

10.5.2.9.3 Rest of Middle East Hormone Replacement Therapy Market By Disease Type

10.5.3 Africa

10.5.3.1 Africa Hormone Replacement Therapy Market by Country

10.5.3.2 Africa Hormone Replacement Therapy Market By Product

10.5.3.3 Africa Hormone Replacement Therapy Market By Route of Administration

10.5.3.4 Africa Hormone Replacement Therapy Market By Disease Type

10.5.3.5 Nigeria

10.5.3.5.1 Nigeria Hormone Replacement Therapy Market By Product

10.5.3.5.2 Nigeria Hormone Replacement Therapy Market By Route of Administration

10.5.3.5.3 Nigeria Hormone Replacement Therapy Market By Disease Type

10.5.3.6 South Africa

10.5.3.6.1 South Africa Hormone Replacement Therapy Market By Product

10.5.3.6.2 South Africa Hormone Replacement Therapy Market By Route of Administration

10.5.3.6.3 South Africa Hormone Replacement Therapy Market By Disease Type

10.5.3.7 Rest of Africa

10.5.3.7.1 Rest of Africa Hormone Replacement Therapy Market By Product

10.5.3.7.2 Rest of Africa Hormone Replacement Therapy Market By Route of Administration

10.5.3.7.3 Rest of Africa Hormone Replacement Therapy Market By Disease Type

10.6 Latin America

10.6.1 Trend Analysis

10.6.2 Latin America Hormone Replacement Therapy Market by country

10.6.3 Latin America Hormone Replacement Therapy Market By Product

10.6.4 Latin America Hormone Replacement Therapy Market By Route of Administration

10.6.5 Latin America Hormone Replacement Therapy Market By Disease Type

10.6.6 Brazil

10.6.6.1 Brazil Hormone Replacement Therapy Market By Product

10.6.6.2 Brazil Hormone Replacement Therapy Market By Route of Administration

10.6.6.3 Brazil Hormone Replacement Therapy Market By Disease Type

10.6.7 Argentina

10.6.7.1 Argentina Hormone Replacement Therapy Market By Product

10.6.7.2 Argentina Hormone Replacement Therapy Market By Route of Administration

10.6.7.3 Argentina Hormone Replacement Therapy Market By Disease Type

10.6.8 Colombia

10.6.8.1 Colombia Hormone Replacement Therapy Market By Product

10.6.8.2 Colombia Hormone Replacement Therapy Market By Route of Administration

10.6.8.3 Colombia Hormone Replacement Therapy Market By Disease Type

10.6.9 Rest of Latin America

10.6.9.1 Rest of Latin America Hormone Replacement Therapy Market By Product

10.6.9.2 Rest of Latin America Hormone Replacement Therapy Market By Route of Administration

10.6.9.3 Rest of Latin America Hormone Replacement Therapy Market By Disease Type

11. Company Profiles

11.1 Eli Lilly and Company

11.1.1 Company Overview

11.1.2 Financial

11.1.3 Products/ Services Offered

11.1.4 The SNS View

11.2 Bayer AG

11.2.1 Company Overview

11.2.2 Financial

11.2.3 Products/ Services Offered

11.2.4 The SNS View

11.3 Noven Pharmaceuticals, Inc.

11.3.1 Company Overview

11.3.2 Financial

11.3.3 Products/ Services Offered

11.3.4 The SNS View

11.4 Pfizer Inc.

11.4.1 Company Overview

11.4.2 Financial

11.4.3 Products/ Services Offered

11.4.4 The SNS View

11.5 Merck & Co., Inc.

11.5.1 Company Overview

11.5.2 Financial

11.5.3 Products/ Services Offered

11.5.4 The SNS View

11.6 Viatris, Inc.

11.6.1 Company Overview

11.6.2 Financial

11.6.3 Products/ Services Offered

11.6.4 The SNS View

11.7 Novo Nordisk A/S

11.7.1 Company Overview

11.7.2 Financial

11.7.3 Products/ Services Offered

11.7.4 The SNS View

11.8 F. Hoffmann-La Roche Ltd.

11.8.1 Company Overview

11.8.2 Financial

11.8.3 Products/ Services Offered

11.8.4 The SNS View

11.9 ASCEND Therapeutics US, LLC.

11.9.1 Company Overview

11.9.2 Financial

11.9.3 Products/ Services Offered

11.9.4 The SNS View

11.10 AbbVie, Inc.

11.10.1 Company Overview

11.10.2 Financial

11.10.3 Products/ Services Offered

11.10.4 The SNS View

12. Competitive Landscape

12.1 Competitive Benchmarking

12.2 Market Share Analysis

12.3 Recent Developments

12.3.1 Industry News

12.3.2 Company News

12.3.3 Mergers & Acquisitions

13. Use Case and Best Practices

14. Conclusion

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

 

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Primary Research

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Data Bank Validation

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.


  •            5000 (33% Discount)


  •            8950 (40% Discount)


  •            3050 (23% Discount)

Start a Conversation

Hi! Click one of our member below to chat on Phone